Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(1.35) by 87.41 percent. This is a 95.53 percent increase over losses of $(3.80) per share from the same period last year.
Amdocs Sees Q4 EPS $1.38-$1.44 Vs $1.5 Est.; Revenue $1.22B-$1.26B Vs $1.25B Est.
Fourth Quarter Fiscal 2023 Outlook
In millions, except per share data
Q4 - 2023
Revenue
$
1,220-$1,260
GAAP Diluted earnings per
